Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$23.34 USD

23.34
2,847,490

-0.15 (-0.64%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $23.33 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Zacks News

Here's Why You Should Add Stryker (SYK) to Your Portfolio

Stryker (SYK) gains from core segments in the second quarter of 2019.

Here's Why You Should Hold Varian Medical (VAR) Stock Now

Varian (VAR) raises the revenue guidance for fiscal 2019.

Here's Why You Should Snap Up Baxter International (BAX) Now

For 2019, Baxter (BAX) expects adjusted earnings per share within $3.34-$3.40.

XRAY vs. COO: Which Stock Is the Better Value Option?

XRAY vs. COO: Which Stock Is the Better Value Option?

Stock Market News For Aug 5, 2019

Benchmarks closed in the red on Friday to post their worst single-day decline in a month.

Stock Market News for Aug 02, 2019

Benchmarks closed lower on Thursday after President Trump announced plans to impose additional tariffs on imports from China.

DENTSPLY SIRONA (XRAY) Q2 Earnings Beat, Revenues Fall Y/Y

DENTSPLY SIRONA (XRAY) raises guidance for 2019 adjusted EPS.

Dentsply International (XRAY) Q2 Earnings Top Estimates

Dentsply (XRAY) delivered earnings and revenue surprises of 6.45% and -2.45%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Dentsply Sirona (XRAY)

Dentsply Sirona (XRAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?

Becton, Dickinson (BDX) expects to gain from core segmental strength in the third quarter.

Will Genetic Testing Drive Invitae's (NVTA) Q2 Earnings?

Invitae (NVTA) expects to deliver a strong second quarter, banking on solid performance of its genetic testing business.

Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract

Illumina's (ILMN) witnessed top-line growth across its high and low throughput categories in the second quarter of 2019.

Why Dentsply (XRAY) Could Beat Earnings Estimates Again

Dentsply (XRAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

What's in the Cards for DaVita (DVA) This Earnings Season?

DaVita (DVA) projects operating income within $460-$465 million for the second quarter.

GNC Holdings (GNC) Q2 Earnings Beat Estimates, Margins Expand

GNC Holdings' (GNC) Q2 revenues decline year over year at each of the three operating segments.

What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?

Better-than-expected performance at Technology & Equipment and growth in emerging markets are likely to aid DENTSPLY SIRONA (XRAY) in Q2 earnings.

Zimmer Biomet (ZBH) Beats on Q2 Earnings, Narrows '19 View

Zimmer Biomet (ZBH) observes strength in the Asia Pacific and EMEA regions as well as in the S.E.T. business.

Can IDEXX's (IDXX) International Growth Drive Q2 Earnings?

In the United States, IDEXX (IDXX) witnesses a strong uptrend in CAG Diagnostic recurring revenues.

Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View

Omnicell (OMCL) aims at product innovation through R&D.

AmerisourceBergen (ABC) Q3 Earnings: What's in the Offing?

Better-than-expected performance at Pharmaceutical Distribution and higher revenues are likely to aid AmerisourceBergen (ABC) in Q3 earnings.

Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates

Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q2 earnings.

Merit Medical (MMSI) Q2 Earnings & Revenues Miss Estimates

Higher revenues and solid segmental performance margins benefit Merit Medical's (MMSI) Q2 earnings. However, contraction in both gross and operating margins remains a concern.

Dentsply International (XRAY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Chemed (CHE) Earnings Top Estimates in Q2, Margins Expand

It is encouraging to note that Chemed (CHE) witnessed solid revenue growth across both of its key subsidiaries.

ResMed's (RMD) Q4 Earnings Beat Estimates, Margins Expand

ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.